Alnylam Pharmaceuticals IncNASDAQ:ALNY
- LAST PRICE244.9100
- TODAY'S CHANGE (%)-1.8900 (-0.7658%)
- Bid / Lots244.7500/ 7
- Ask / Lots245.0700/ 7
- Open / Previous Close248.9000 / 246.8000
- Day Range
- 52 Week Range
- Volume188,161
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ALNY |
|---|---|---|
| 09:32 ET | 2938 | 248.18 |
| 09:33 ET | 400 | 248.52 |
| 09:35 ET | 400 | 246.85 |
| 09:37 ET | 200 | 246.75 |
| 09:42 ET | 1200 | 246 |
| 09:46 ET | 174 | 245.6029 |
| 09:48 ET | 300 | 246.85 |
| 09:50 ET | 2712 | 246.41 |
| 09:51 ET | 100 | 246.955 |
| 09:55 ET | 251 | 246.455 |
| 10:00 ET | 400 | 246.51 |
| 10:02 ET | 1558 | 245.82 |
| 10:04 ET | 100 | 246.07 |
| 10:06 ET | 603 | 245.59 |
| 10:08 ET | 100 | 245.81 |
| 10:09 ET | 800 | 246.335 |
| 10:13 ET | 100 | 246.335 |
| 10:15 ET | 400 | 246.35 |
| 10:18 ET | 3893 | 247.45 |
| 10:20 ET | 400 | 247.465 |
| 10:22 ET | 102 | 248.22 |
| 10:24 ET | 800 | 248.405 |
| 10:26 ET | 600 | 248.315 |
| 10:27 ET | 1900 | 247.67 |
| 10:31 ET | 200 | 247.33 |
| 10:33 ET | 600 | 246.44 |
| 10:36 ET | 400 | 246.67 |
| 10:38 ET | 3180 | 246.75 |
| 10:40 ET | 2124 | 246.825 |
| 10:42 ET | 100 | 246.69 |
| 10:44 ET | 1229 | 246.61 |
| 10:45 ET | 146 | 247.499 |
| 10:47 ET | 100 | 247.07 |
| 10:51 ET | 1746 | 246.9 |
| 10:54 ET | 313 | 246.5 |
| 10:56 ET | 200 | 246.3 |
| 10:58 ET | 400 | 246.225 |
| 11:00 ET | 483 | 245.92 |
| 11:02 ET | 100 | 246.08 |
| 11:03 ET | 1184 | 246.32 |
| 11:05 ET | 212 | 246.245 |
| 11:07 ET | 819 | 246.415 |
| 11:09 ET | 300 | 246.41 |
| 11:12 ET | 2120 | 246.955 |
| 11:14 ET | 1350 | 246.96 |
| 11:16 ET | 1000 | 246.6 |
| 11:18 ET | 300 | 246.41 |
| 11:23 ET | 300 | 246.62 |
| 11:25 ET | 1500 | 246.57 |
| 11:27 ET | 5227 | 247.01 |
| 11:30 ET | 447 | 247.34 |
| 11:32 ET | 100 | 247.315 |
| 11:34 ET | 200 | 247.3 |
| 11:38 ET | 730 | 247.4 |
| 11:39 ET | 4037 | 247.81 |
| 11:41 ET | 100 | 247.805 |
| 11:43 ET | 400 | 247.755 |
| 11:45 ET | 1920 | 247.38 |
| 11:48 ET | 500 | 247.15 |
| 11:50 ET | 200 | 247.24 |
| 11:52 ET | 2301 | 247.2425 |
| 11:54 ET | 200 | 246.93 |
| 11:56 ET | 1300 | 247.155 |
| 11:57 ET | 100 | 246.92 |
| 11:59 ET | 600 | 246.85 |
| 12:01 ET | 1294 | 247.03 |
| 12:03 ET | 432 | 247.03 |
| 12:06 ET | 232 | 247.07 |
| 12:08 ET | 200 | 246.79 |
| 12:12 ET | 400 | 246.46 |
| 12:15 ET | 2931 | 246.4 |
| 12:17 ET | 2600 | 246.19 |
| 12:21 ET | 1506 | 247.01 |
| 12:24 ET | 100 | 246.84 |
| 12:28 ET | 1300 | 246.95 |
| 12:30 ET | 1411 | 246.82 |
| 12:32 ET | 300 | 246.7 |
| 12:33 ET | 1100 | 246.885 |
| 12:35 ET | 106 | 246.605 |
| 12:39 ET | 100 | 246.955 |
| 12:42 ET | 970 | 246.7518 |
| 12:44 ET | 100 | 246.77 |
| 12:46 ET | 200 | 246.77 |
| 12:48 ET | 300 | 246.785 |
| 12:50 ET | 200 | 246.86 |
| 12:53 ET | 1013 | 246.13 |
| 12:57 ET | 200 | 245.62 |
| 01:02 ET | 100 | 245.905 |
| 01:04 ET | 200 | 245.905 |
| 01:06 ET | 100 | 245.985 |
| 01:08 ET | 1700 | 246.115 |
| 01:11 ET | 600 | 246.46 |
| 01:13 ET | 100 | 246.47 |
| 01:20 ET | 100 | 246.445 |
| 01:22 ET | 100 | 246.34 |
| 01:24 ET | 900 | 246.215 |
| 01:26 ET | 100 | 246.15 |
| 01:36 ET | 100 | 245.875 |
| 01:38 ET | 100 | 245.38 |
| 01:40 ET | 1300 | 245.555 |
| 01:42 ET | 252 | 245.28 |
| 01:44 ET | 1525 | 244.965 |
| 01:45 ET | 625 | 245.16 |
| 01:47 ET | 100 | 244.96 |
| 01:49 ET | 2558 | 244.945 |
| 01:51 ET | 200 | 244.9 |
| 01:54 ET | 650 | 244.985 |
| 01:58 ET | 643 | 244.99 |
| 02:00 ET | 600 | 245.015 |
| 02:03 ET | 3471 | 244.74 |
| 02:12 ET | 400 | 244.63 |
| 02:14 ET | 800 | 244.775 |
| 02:16 ET | 200 | 244.75 |
| 02:18 ET | 1237 | 244.815 |
| 02:20 ET | 200 | 244.57 |
| 02:21 ET | 100 | 244.77 |
| 02:23 ET | 100 | 244.8 |
| 02:25 ET | 600 | 245.045 |
| 02:27 ET | 558 | 244.845 |
| 02:34 ET | 200 | 244.91 |
Nov 18, 2024
DJ Alnylam Pharmaceuticals Price Target Maintained With a $296.00/Share by Piper Sandler, from 1:10PM ET on Monday Nov 18, 2024 by Dow Jones
1:10PM ET on Monday Nov 18, 2024 by Dow JonesDJ Alnylam Pharmaceuticals Price Target Maintained With a $400.00/Share by HC Wainwright & Co., from 12:59PM ET on Monday Nov 18, 2024 by Dow Jones
12:59PM ET on Monday Nov 18, 2024 by Dow Jones
Nov 17, 2024
Nov 12, 2024
DJ Alnylam Pharmaceuticals Cut to Underperform From Peer Perform by Wolfe Research, from 5:31AM ET on Tuesday Nov 12, 2024 by Dow Jones
5:31AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 4, 2024
Alnylam to Webcast Presentations at Upcoming November Investor Conferences, from 8:00AM ET on Monday Nov 04, 2024 by Dow Jones
8:00AM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Alnylam Pharmaceuticals Inc | 31.8B | -93.4x | --- |
Royalty Pharma PLC | 15.6B | 10.3x | +1.83% |
Endo Inc | 1.9B | 0.4x | --- |
Prestige Consumer Healthcare Inc | 4.2B | 20.7x | --- |
Novo Nordisk A/S | 345.9B | 35.4x | +18.50% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Company Information
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. In addition, the Company develops Cemdisiran to treat complement-mediated diseases, Belcesiran for the treatment of alpha-1 liver disease, Elebsiran, Zilebesiran, ALN-APP, ALN-HSD, Fitusiran, and others.
Contact Information
- Headquarters
- 675 W Kendall StCAMBRIDGE, MA, United States 02142-1168
- Phone
- 617-551-8200
- Fax
- 617-551-8101
Executives
- Independent Chairman of the Board
- Amy Schulman
- Chief Executive Officer, Director
- Yvonne Greenstreet
- Chief Financial Officer, Executive Vice President
- Jeffrey Poulton
- Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
- Kevin Fitzgerald
- Chief Medical Officer, Executive Vice President - Development and Medical Affairs
- Pushkal Garg
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $31.8B |
|---|---|
Revenue (TTM) | $2.1B |
Shares Outstanding | 129.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.32 |
EPS | $-2.62 |
Book Value | $-1.75 |
P/E Ratio | -93.4x |
Price/Sales (TTM) | 15.2 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -8.98% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
